Moleculin Biotech, Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MOLECULIN BIOTECH, INC. | |
| By: | /s/ Walter V. Klemp |
| Walter V. Klemp, | |
| Chief Executive Officer and Chairman |
Date: March 21, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Walter V. Klemp | Chief Executive Officer and Chairman | March 21, 2025 |
| Walter V. Klemp | (Principal Executive Officer) | |
| /s/ Jonathan P. Foster | Executive Vice President and | March 21, 2025 |
| Jonathan P. Foster | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
| /s/ Robert George | Director | March 21, 2025 |
| Robert George | ||
| /s/ Michael Cannon | Director | March 21, 2025 |
| Michael Cannon | ||
| /s/ John Climaco | Director | March 21, 2025 |
| John Climaco | ||
| /s/ Elizabeth Cermak | Director | March 21, 2025 |
| Elizabeth Cermak | ||
| /s/ Joy Yan | Director | March 21, 2025 |
| Joy Yan | ||
Index to Consolidated Financial Statements
| PAGE | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248) | 60 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | 61 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2024 and 2023 | 62 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2024 and 2023 | 63 |
| Consolidated Statements of Stockholders' Equity for the Years ended December 31, 2024 and 2023 | 64 |
| Notes to Consolidated Financial Statements | 65 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.